Advisory Firm Appointment Underscores MetAlert, Inc. (MLRT) Strategy Amid Growth Stage and New Patient Location-tracking Technology Rollout

• Pioneering GPS-enabled location device developer MetAlert is building on two decades of experience with new products designed to broaden its suite of technology for remote patient monitoring (“RPM”) in an unobtrusive manner plus monitoring seniors for falls
• MetAlert recently announced that it has engaged the financial strategy advisory firm Joseph Gunnar & Co., LLC to help direct its decisions ranging from acquisitions to potential up listing on a national exchange
• The company’s products include its flagship patented shoe insole device enabled with GPS, Bluetooth, and Wi-Fi functionality for tracking seniors or people with autism prone to wandering and getting lost, as well as protecting potential kidnapping targets
• MetAlert’s latest product developments provide artificial intelligence as an accessory to identify fall risks and provide related analysis of patients’ physical functioning, while allowing the patient to maintain a degree of privacy and independence

Medical patient location device developer MetAlert (OTC: MLRT) is launching a suite of wearable companion products to its innovative SmartSole shoe insole units and, on the heels of rebranding the company to better represent its strategic direction, recently announced that it has engaged financial advisory firm Joseph Gunnar & Co., LLC to guide its financing and acquisition decisions.

“MetAlert is approaching the inflection point of its growth curve by its ability to sell a multitude of products and services to a broader audience, which will result in greater revenue per user (“RPU”),” MetAlert CEO Patrick Bertagna stated (https://ibn.fm/0eYGw). “We are thrilled to align with a proven advisor like Joseph Gunnar in our quest to maximize shareholder value.”

The patented GPS-enabled SmartSole is a non-intrusive tracking device designed to monitor the location of people with cognitive memory disorders such as Alzheimer’s Disease who tend to get lost or wander. The tech-designed insole may also be used by people at risk of kidnapping, such as children, government employees and select professionals.

A next-generation shoe insole branded SmartSole plus incorporates biometric sensors paired with smart analytics to analyze the wearer’s movements for assessing overall health and wellness, and the company’s most recent product rollout — the in-home RoomMate system — uses 3D infrared motion-sensitive technology to allow caregivers to remotely monitor fall-prone loved ones in an unobtrusive manner.

Such developments have given the location technology pioneer a new progressive profile designed to encourage investors and strengthen the company’s profitability (https://ibn.fm/eTt7E).

The market potential for location and fall-monitoring devices is demonstrated by Centers for Disease Control and Prevention reporting that notes U.S. emergency departments treat 3 million older adults each year for fall injuries and more than 650,000 people are believed to have died each year as a result of accidental falls (https://ibn.fm/IGNcY). 

MetAlert’s international distribution supply chain serves customers in over 40 countries as well as U.S. clients ranging from police departments to assisted living facilities.

Developments anticipated during the first months of 2023 include the rollout of Bluetooth-enabled devices that will collect patients’ health data such as their vitals and, in connection with the GPS SmartSole plus HUB and artificial intelligence software, will analyze trends and provide responsiveness according to preset alert parameters.

A small GPS tracker shorter than the length of a credit card will provide the same functionality as the insoles and have a two-week battery life between charging.

For more information, visit the company’s website at www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.